<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406938</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2304</org_study_id>
    <secondary_id>2011-000767-27</secondary_id>
    <nct_id>NCT01406938</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens</brief_title>
  <acronym>SCULPTURE</acronym>
  <official_title>A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of two different doses and two different dose
      regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic,
      plaque-type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52</measure>
    <time_frame>Week 40 , week 52</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12</measure>
    <time_frame>Baseline, week 2, 3 , 4, 8, 12</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52</measure>
    <time_frame>Baseline, week 12,16,20,24,28,32,36,40,44,48 and week 52</time_frame>
    <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)</measure>
    <time_frame>Baseline, week 2, 4, 6, 8, 12</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))</measure>
    <time_frame>Baseline, week 16,20,24,28,32,36,40,44,48, and Week 52</time_frame>
    <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)</measure>
    <time_frame>Baseline to week 2, 4, 8, 12</time_frame>
    <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example &quot;confined to bed&quot;) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)</measure>
    <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
    <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example &quot;confined to bed&quot;) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)</measure>
    <time_frame>Baseline to week 2, 4, 8, 12</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)</measure>
    <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)</measure>
    <time_frame>Baseline to week 2, 4, 6, 8, 12</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).</measure>
    <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52</time_frame>
    <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Relapse (Weeks) From Week 12.</measure>
    <time_frame>Week 12 to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
    <description>Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</measure>
    <time_frame>Week 12</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</measure>
    <time_frame>Week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1</measure>
    <time_frame>Week 16, 20, 24,28,32,36,40,44,48,and Week 52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12</measure>
    <time_frame>week 16, 20, 24,28,32,36,40,44,48,and Week 52</time_frame>
    <description>The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Anti-secukinumab Antibodies</measure>
    <time_frame>Baseline, weeks 12, 24, 52 and 60</time_frame>
    <description>The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">967</enrollment>
  <condition>Moderate to Severe Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>AIN457150 mg- Induction period Only(IPO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg - IPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>secukinumab- 2 x 150mg injections per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg FI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 s.c. secukinumab 150 mg injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150 mg- Start of relapse (SoR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg- SoR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 s.c. secukinumab 150 mg injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 150mg</intervention_name>
    <description>(1 injection per dose) and placebo to secukinumab 150 mg</description>
    <arm_group_label>AIN457150 mg- Induction period Only(IPO)</arm_group_label>
    <arm_group_label>AIN457 150 mg - Fixed Interval (FI)</arm_group_label>
    <arm_group_label>AIN457 150 mg- Start of relapse (SoR)</arm_group_label>
    <other_name>secukinumab 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 300mg</intervention_name>
    <description>secukinumab 150 mg (2 injections per dose)</description>
    <arm_group_label>AIN457 300 mg - IPO</arm_group_label>
    <arm_group_label>AIN457 300 mg FI</arm_group_label>
    <arm_group_label>AIN457 300 mg- SoR</arm_group_label>
    <other_name>secukinumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.

        Severity of disease meeting all of the following three criteria:

          -  PASI score of 12 or greater,

          -  Investigator's Global Assessment (IGA) score of 3 or greater

          -  Total body surface area (BSA) affected of 10% or greater.

          -  Inadequate control by prior use of topical treatment, phototherapy and/or systemic
             therapy.

        Exclusion criteria:

          -  Current forms of psoriasis other than chronic plaque-type psoriasis (for example,
             pustular, erythrodermic, guttate).

          -  Current drug-induced psoriasis.

          -  Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.

          -  Significant medical problems such as uncontrolled hypertension, congestive heart
             failure or a condition that significantly immunocompromises the subject.

          -  Hematological abnormalities.

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             untreated tuberculosis.

          -  History of lymphoproliferative disease or history of malignancy of any organ system
             within the past 5 years.

          -  Pregnant or nursing (lactating) women.

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1231</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <state>CZE</state>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 8</city>
        <state>CZE</state>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno - Bohunice</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre-Benite Cédex</city>
        <zip>F-69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Wildbad</city>
        <zip>75323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buchholz i. d. Nordheide</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dippoldiswalde-Schmiedeberg</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pommelsbrunn</city>
        <zip>91224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440 010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kisarazu</city>
        <state>Chiba</state>
        <zip>292-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa-city</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>550-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>308205</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>SK-81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>05845</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE7 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poole</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>1000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>7000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <results_first_submitted>February 13, 2015</results_first_submitted>
  <results_first_submitted_qc>April 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2015</results_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>plaque</keyword>
  <keyword>inflammatory skin disease</keyword>
  <keyword>scaly patches</keyword>
  <keyword>AIN457</keyword>
  <keyword>secukinumab</keyword>
  <keyword>Moderate to Severe Plaque-type Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>966 patients randomized to two groups, induction secukinumab 150 mg or secukinumab 300 mg. Most randomized patients, 928/966 completed the 12-week induction period. 928 completed the induction period, a total of 843 were re-randomized to the maintenance period to either fixed interval dosing or start of relapse dosing at their respective dose level</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457150 mg- Induction Period Only(IPO)</title>
          <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300 mg - IPO</title>
          <description>secukinumab- 2 x 150mg injections per dose</description>
        </group>
        <group group_id="P3">
          <title>AIN457 150 mg - Fixed Interval (FI)</title>
          <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
        </group>
        <group group_id="P4">
          <title>AIN457 300 mg FI</title>
          <description>2 s.c. secukinumab 150 mg injections</description>
        </group>
        <group group_id="P5">
          <title>AIN457 150 mg- Start of Relapse (SoR)</title>
          <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
        </group>
        <group group_id="P6">
          <title>AIN457 300 mg- SoR</title>
          <description>2 s.c. secukinumab 150 mg injections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS:Patients Assigned Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="482"/>
                <participants group_id="P2" count="483"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="464"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="203"/>
                <participants group_id="P4" count="217"/>
                <participants group_id="P5" count="206"/>
                <participants group_id="P6" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS: Patients Assigned Treatment Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="203"/>
                <participants group_id="P4" count="216"/>
                <participants group_id="P5" count="206"/>
                <participants group_id="P6" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="199"/>
                <participants group_id="P5" count="181"/>
                <participants group_id="P6" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full analysis set (FAS) was comprised of all patients to whom study treatment had been assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>AIN457150 mg- Induction Period Only(IPO)</title>
          <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300 mg - IPO</title>
          <description>secukinumab- 2 x 150mg injections per dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="482"/>
            <count group_id="B2" value="484"/>
            <count group_id="B3" value="966"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="12.83"/>
                    <measurement group_id="B2" value="46.7" spread="12.83"/>
                    <measurement group_id="B3" value="46.0" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
        <time_frame>Week 40 , week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="62.1"/>
                    <measurement group_id="O4" value="78.2"/>
                    <measurement group_id="O5" value="52.4"/>
                    <measurement group_id="O6" value="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
        <time_frame>Baseline, week 2, 3 , 4, 8, 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="483"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.46" spread="6.338"/>
                    <measurement group_id="O2" value="-9.28" spread="6.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.13" spread="7.826"/>
                    <measurement group_id="O2" value="-12.97" spread="7.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.18" spread="8.956"/>
                    <measurement group_id="O2" value="-15.90" spread="8.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.69" spread="10.147"/>
                    <measurement group_id="O2" value="-19.56" spread="9.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.71" spread="10.804"/>
                    <measurement group_id="O2" value="-20.89" spread="9.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52</title>
        <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
        <time_frame>Baseline, week 12,16,20,24,28,32,36,40,44,48 and week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52</title>
          <description>PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-21.52" spread="9.553"/>
                    <measurement group_id="O4" value="-22.32" spread="8.943"/>
                    <measurement group_id="O5" value="-23.19" spread="11.063"/>
                    <measurement group_id="O6" value="-21.58" spread="9.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-21.23" spread="9.676"/>
                    <measurement group_id="O4" value="-22.61" spread="9.310"/>
                    <measurement group_id="O5" value="-23.26" spread="11.158"/>
                    <measurement group_id="O6" value="-21.58" spread="9.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-20.79" spread="9.739"/>
                    <measurement group_id="O4" value="-22.47" spread="9.237"/>
                    <measurement group_id="O5" value="-22.28" spread="11.548"/>
                    <measurement group_id="O6" value="-20.97" spread="9.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-20.61" spread="9.745"/>
                    <measurement group_id="O4" value="-22.30" spread="9.262"/>
                    <measurement group_id="O5" value="-21.36" spread="11.938"/>
                    <measurement group_id="O6" value="-20.09" spread="9.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-20.29" spread="9.730"/>
                    <measurement group_id="O4" value="-22.13" spread="9.244"/>
                    <measurement group_id="O5" value="-20.53" spread="11.754"/>
                    <measurement group_id="O6" value="-19.27" spread="9.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-20.11" spread="9.847"/>
                    <measurement group_id="O4" value="-21.98" spread="9.195"/>
                    <measurement group_id="O5" value="-19.41" spread="10.962"/>
                    <measurement group_id="O6" value="-18.68" spread="9.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-19.82" spread="9.908"/>
                    <measurement group_id="O4" value="-21.79" spread="9.324"/>
                    <measurement group_id="O5" value="-18.86" spread="10.625"/>
                    <measurement group_id="O6" value="-18.14" spread="9.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-19.51" spread="9.821"/>
                    <measurement group_id="O4" value="-21.71" spread="9.369"/>
                    <measurement group_id="O5" value="-18.30" spread="10.660"/>
                    <measurement group_id="O6" value="-17.89" spread="9.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-19.40" spread="9.691"/>
                    <measurement group_id="O4" value="-21.58" spread="9.398"/>
                    <measurement group_id="O5" value="-17.73" spread="11.041"/>
                    <measurement group_id="O6" value="-17.03" spread="9.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-19.04" spread="10.093"/>
                    <measurement group_id="O4" value="-21.34" spread="9.681"/>
                    <measurement group_id="O5" value="-17.48" spread="10.638"/>
                    <measurement group_id="O6" value="-16.58" spread="9.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-18.79" spread="9.904"/>
                    <measurement group_id="O4" value="21.47" spread="9.402"/>
                    <measurement group_id="O5" value="-17.40" spread="10.719"/>
                    <measurement group_id="O6" value="-16.33" spread="8.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe</description>
        <time_frame>Baseline, week 2, 4, 6, 8, 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Percent of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="483"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8"/>
                    <measurement group_id="O2" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))</title>
        <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant’s disease state at the time of the assessments and does not attempt a comparison to any of the participant’s previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe</description>
        <time_frame>Baseline, week 16,20,24,28,32,36,40,44,48, and Week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving Psoriasis Area &amp; Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))</title>
          <description>The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant’s disease state at the time of the assessments and does not attempt a comparison to any of the participant’s previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="70.9"/>
                    <measurement group_id="O4" value="82.4"/>
                    <measurement group_id="O5" value="74.8"/>
                    <measurement group_id="O6" value="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="90.1"/>
                    <measurement group_id="O4" value="92.1"/>
                    <measurement group_id="O5" value="92.7"/>
                    <measurement group_id="O6" value="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="96.1"/>
                    <measurement group_id="O4" value="97.7"/>
                    <measurement group_id="O5" value="98.1"/>
                    <measurement group_id="O6" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="59.1"/>
                    <measurement group_id="O4" value="75.5"/>
                    <measurement group_id="O5" value="68.4"/>
                    <measurement group_id="O6" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="27.6"/>
                    <measurement group_id="O4" value="31.5"/>
                    <measurement group_id="O5" value="22.3"/>
                    <measurement group_id="O6" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="75.5"/>
                    <measurement group_id="O5" value="64.6"/>
                    <measurement group_id="O6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="85.7"/>
                    <measurement group_id="O4" value="90.3"/>
                    <measurement group_id="O5" value="81.6"/>
                    <measurement group_id="O6" value="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="94.6"/>
                    <measurement group_id="O4" value="97.7"/>
                    <measurement group_id="O5" value="92.2"/>
                    <measurement group_id="O6" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="62.6"/>
                    <measurement group_id="O4" value="74.5"/>
                    <measurement group_id="O5" value="55.8"/>
                    <measurement group_id="O6" value="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="29.1"/>
                    <measurement group_id="O4" value="35.6"/>
                    <measurement group_id="O5" value="24.8"/>
                    <measurement group_id="O6" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="67.5"/>
                    <measurement group_id="O4" value="76.9"/>
                    <measurement group_id="O5" value="56.3"/>
                    <measurement group_id="O6" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="80.3"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="72.3"/>
                    <measurement group_id="O6" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="93.1"/>
                    <measurement group_id="O4" value="94.9"/>
                    <measurement group_id="O5" value="89.3"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="66.5"/>
                    <measurement group_id="O4" value="74.1"/>
                    <measurement group_id="O5" value="51.5"/>
                    <measurement group_id="O6" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="29.1"/>
                    <measurement group_id="O4" value="36.1"/>
                    <measurement group_id="O5" value="19.9"/>
                    <measurement group_id="O6" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="65.5"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="44.7"/>
                    <measurement group_id="O6" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="77.3"/>
                    <measurement group_id="O4" value="85.6"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="92.6"/>
                    <measurement group_id="O4" value="93.5"/>
                    <measurement group_id="O5" value="87.4"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="70.4"/>
                    <measurement group_id="O5" value="40.8"/>
                    <measurement group_id="O6" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="29.6"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="15.5"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="74.1"/>
                    <measurement group_id="O5" value="33.5"/>
                    <measurement group_id="O6" value="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="74.9"/>
                    <measurement group_id="O4" value="84.3"/>
                    <measurement group_id="O5" value="50.5"/>
                    <measurement group_id="O6" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="91.1"/>
                    <measurement group_id="O4" value="92.6"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="58.6"/>
                    <measurement group_id="O4" value="74.1"/>
                    <measurement group_id="O5" value="32.5"/>
                    <measurement group_id="O6" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="30.5"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="10.7"/>
                    <measurement group_id="O6" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="59.6"/>
                    <measurement group_id="O4" value="70.4"/>
                    <measurement group_id="O5" value="27.2"/>
                    <measurement group_id="O6" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="71.4"/>
                    <measurement group_id="O4" value="82.9"/>
                    <measurement group_id="O5" value="45.1"/>
                    <measurement group_id="O6" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="87.7"/>
                    <measurement group_id="O4" value="91.2"/>
                    <measurement group_id="O5" value="78.6"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="54.7"/>
                    <measurement group_id="O4" value="68.1"/>
                    <measurement group_id="O5" value="24.8"/>
                    <measurement group_id="O6" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="2.9"/>
                    <measurement group_id="O6" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="53.2"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="26.2"/>
                    <measurement group_id="O6" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="81.5"/>
                    <measurement group_id="O5" value="42.2"/>
                    <measurement group_id="O6" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="87.7"/>
                    <measurement group_id="O4" value="90.7"/>
                    <measurement group_id="O5" value="74.8"/>
                    <measurement group_id="O6" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="52.2"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="18.9"/>
                    <measurement group_id="O6" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="26.1"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="1.9"/>
                    <measurement group_id="O6" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="52.7"/>
                    <measurement group_id="O4" value="64.8"/>
                    <measurement group_id="O5" value="20.4"/>
                    <measurement group_id="O6" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="80.1"/>
                    <measurement group_id="O5" value="37.4"/>
                    <measurement group_id="O6" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="84.2"/>
                    <measurement group_id="O4" value="92.1"/>
                    <measurement group_id="O5" value="72.8"/>
                    <measurement group_id="O6" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="49.8"/>
                    <measurement group_id="O4" value="66.2"/>
                    <measurement group_id="O5" value="16.5"/>
                    <measurement group_id="O6" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="22.7"/>
                    <measurement group_id="O4" value="39.8"/>
                    <measurement group_id="O5" value="1.5"/>
                    <measurement group_id="O6" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="51.7"/>
                    <measurement group_id="O4" value="64.8"/>
                    <measurement group_id="O5" value="20.4"/>
                    <measurement group_id="O6" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="65.5"/>
                    <measurement group_id="O4" value="78.7"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="89.8"/>
                    <measurement group_id="O5" value="74.8"/>
                    <measurement group_id="O6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="49.8"/>
                    <measurement group_id="O4" value="62.5"/>
                    <measurement group_id="O5" value="12.6"/>
                    <measurement group_id="O6" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="38.4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="47.3"/>
                    <measurement group_id="O4" value="59.3"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="62.1"/>
                    <measurement group_id="O4" value="78.2"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="83.7"/>
                    <measurement group_id="O4" value="87.5"/>
                    <measurement group_id="O5" value="73.8"/>
                    <measurement group_id="O6" value="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="45.8"/>
                    <measurement group_id="O4" value="59.7"/>
                    <measurement group_id="O5" value="11.2"/>
                    <measurement group_id="O6" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="36.6"/>
                    <measurement group_id="O5" value="2.4"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)</title>
        <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
        <time_frame>Baseline to week 2, 4, 8, 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)</title>
          <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="483"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="14.64"/>
                    <measurement group_id="O2" value="7.6" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="17.79"/>
                    <measurement group_id="O2" value="13.6" spread="18.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="20.79"/>
                    <measurement group_id="O2" value="18.3" spread="21.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="23.47"/>
                    <measurement group_id="O2" value="21.2" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)</title>
        <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
        <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)</title>
          <description>ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example “confined to bed”) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="21.4" spread="25.11"/>
                    <measurement group_id="O4" value="23" spread="22.44"/>
                    <measurement group_id="O5" value="23.4" spread="25.31"/>
                    <measurement group_id="O6" value="23.9" spread="26.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="20.6" spread="25.07"/>
                    <measurement group_id="O4" value="23" spread="23.27"/>
                    <measurement group_id="O5" value="22.1" spread="26.04"/>
                    <measurement group_id="O6" value="22.4" spread="27.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="20.6" spread="25.05"/>
                    <measurement group_id="O4" value="22.9" spread="23.32"/>
                    <measurement group_id="O5" value="20" spread="26.66"/>
                    <measurement group_id="O6" value="22.3" spread="26.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.4" spread="26.46"/>
                    <measurement group_id="O4" value="23" spread="22.71"/>
                    <measurement group_id="O5" value="19.3" spread="25.07"/>
                    <measurement group_id="O6" value="20.4" spread="26.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="20.4" spread="24.95"/>
                    <measurement group_id="O4" value="22.8" spread="23.22"/>
                    <measurement group_id="O5" value="17.9" spread="24.97"/>
                    <measurement group_id="O6" value="18.8" spread="25.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.6" spread="25.79"/>
                    <measurement group_id="O4" value="23" spread="22.67"/>
                    <measurement group_id="O5" value="17.4" spread="24.30"/>
                    <measurement group_id="O6" value="17.7" spread="26.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.8" spread="25.39"/>
                    <measurement group_id="O4" value="22.8" spread="22.69"/>
                    <measurement group_id="O5" value="16.3" spread="23.53"/>
                    <measurement group_id="O6" value="16.4" spread="26.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.8" spread="25.53"/>
                    <measurement group_id="O4" value="22.3" spread="23.10"/>
                    <measurement group_id="O5" value="15.4" spread="23.70"/>
                    <measurement group_id="O6" value="14.9" spread="26.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.7" spread="25.33"/>
                    <measurement group_id="O4" value="22.7" spread="22.85"/>
                    <measurement group_id="O5" value="16.2" spread="23.17"/>
                    <measurement group_id="O6" value="13.4" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="18.3" spread="25.63"/>
                    <measurement group_id="O4" value="23" spread="22.40"/>
                    <measurement group_id="O5" value="16.7" spread="23.30"/>
                    <measurement group_id="O6" value="13.4" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Baseline to week 2, 4, 8, 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="483"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 DLQI total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.02"/>
                    <measurement group_id="O2" value="-6" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 DLQI total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="6.11"/>
                    <measurement group_id="O2" value="-8.7" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 DLQI total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="6.40"/>
                    <measurement group_id="O2" value="-10.3" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 DLQI total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="6.75"/>
                    <measurement group_id="O2" value="-11" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-11" spread="6.63"/>
                    <measurement group_id="O4" value="-11.4" spread="7.12"/>
                    <measurement group_id="O5" value="-11.4" spread="6.98"/>
                    <measurement group_id="O6" value="-11.3" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.6" spread="6.50"/>
                    <measurement group_id="O4" value="-11" spread="7.18"/>
                    <measurement group_id="O5" value="-10.6" spread="7.55"/>
                    <measurement group_id="O6" value="-11" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.5" spread="6.67"/>
                    <measurement group_id="O4" value="-11.1" spread="7.39"/>
                    <measurement group_id="O5" value="-10.1" spread="7.65"/>
                    <measurement group_id="O6" value="-10.3" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.5" spread="6.68"/>
                    <measurement group_id="O4" value="-11" spread="7.22"/>
                    <measurement group_id="O5" value="-9.7" spread="7.39"/>
                    <measurement group_id="O6" value="-9.5" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.5" spread="6.76"/>
                    <measurement group_id="O4" value="-10.9" spread="7.17"/>
                    <measurement group_id="O5" value="-8.6" spread="7.66"/>
                    <measurement group_id="O6" value="-8.9" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.2" spread="6.94"/>
                    <measurement group_id="O4" value="-10.9" spread="7.30"/>
                    <measurement group_id="O5" value="-8.6" spread="7.55"/>
                    <measurement group_id="O6" value="-8.5" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.1" spread="6.83"/>
                    <measurement group_id="O4" value="-10.8" spread="7.33"/>
                    <measurement group_id="O5" value="-8.4" spread="7.22"/>
                    <measurement group_id="O6" value="-8.5" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10.2" spread="6.72"/>
                    <measurement group_id="O4" value="-10.8" spread="7.46"/>
                    <measurement group_id="O5" value="-8.4" spread="7.07"/>
                    <measurement group_id="O6" value="-8.6" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-10" spread="6.57"/>
                    <measurement group_id="O4" value="-10.8" spread="7.38"/>
                    <measurement group_id="O5" value="-8.6" spread="7.41"/>
                    <measurement group_id="O6" value="7.9" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="-9.8" spread="7.06"/>
                    <measurement group_id="O4" value="-10.9" spread="7.31"/>
                    <measurement group_id="O5" value="-8.4" spread="7.46"/>
                    <measurement group_id="O6" value="-7.6" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Baseline to week 2, 4, 6, 8, 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="482"/>
                <count group_id="O2" value="484"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=463,471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=479,482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=479,482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=479,482)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).</title>
        <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
        <time_frame>Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).</title>
          <description>The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Percent of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 (n=199,209,202,215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="59.8"/>
                    <measurement group_id="O4" value="66.5"/>
                    <measurement group_id="O5" value="58.4"/>
                    <measurement group_id="O6" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=202,213,205,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="57.4"/>
                    <measurement group_id="O4" value="67.6"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="58.4"/>
                    <measurement group_id="O4" value="68.7"/>
                    <measurement group_id="O5" value="53.9"/>
                    <measurement group_id="O6" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="57.9"/>
                    <measurement group_id="O4" value="70.1"/>
                    <measurement group_id="O5" value="47.6"/>
                    <measurement group_id="O6" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="57.9"/>
                    <measurement group_id="O4" value="67.8"/>
                    <measurement group_id="O5" value="37.9"/>
                    <measurement group_id="O6" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="58.4"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="39.8"/>
                    <measurement group_id="O6" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="66.4"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="59.9"/>
                    <measurement group_id="O4" value="68.7"/>
                    <measurement group_id="O5" value="31.6"/>
                    <measurement group_id="O6" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="67.3"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=202,214,206,217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="56.4"/>
                    <measurement group_id="O4" value="69.2"/>
                    <measurement group_id="O5" value="31.1"/>
                    <measurement group_id="O6" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Relapse (Weeks) From Week 12.</title>
        <description>Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement</description>
        <time_frame>Week 12 to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Relapse (Weeks) From Week 12.</title>
          <description>Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Number of weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA">not estimable due to insufficient events at the time of analysis</measurement>
                    <measurement group_id="O4" value="NA">not estimable due to insufficient events at the time of analysis</measurement>
                    <measurement group_id="O5" value="NA">not estimable due to insufficient events at the time of analysis</measurement>
                    <measurement group_id="O6" value="302" lower_limit="302">not estimable due to insufficient events at the time of analysis</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 IGA 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="4.3"/>
                    <measurement group_id="O6" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="86.1"/>
                    <measurement group_id="O5" value="60.9"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="77.8"/>
                    <measurement group_id="O5" value="21.7"/>
                    <measurement group_id="O6" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="52.8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 16, 20, 24,28,32,36,40,44,48,and Week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 50 Visit 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="1.5"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="4.4"/>
                    <measurement group_id="O6" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="2.4"/>
                    <measurement group_id="O6" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="4.9"/>
                    <measurement group_id="O6" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="6.8"/>
                    <measurement group_id="O6" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="10.2"/>
                    <measurement group_id="O6" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="8.4"/>
                    <measurement group_id="O4" value="7.9"/>
                    <measurement group_id="O5" value="8.7"/>
                    <measurement group_id="O6" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 Visit 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="72.9"/>
                    <measurement group_id="O4" value="79.6"/>
                    <measurement group_id="O5" value="53.9"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="3.9"/>
                    <measurement group_id="O6" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="6.8"/>
                    <measurement group_id="O6" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="8.3"/>
                    <measurement group_id="O6" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="7.8"/>
                    <measurement group_id="O6" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="11.2"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="10.7"/>
                    <measurement group_id="O6" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="11.7"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="9.2"/>
                    <measurement group_id="O6" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="4.2"/>
                    <measurement group_id="O5" value="9.7"/>
                    <measurement group_id="O6" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="8.8"/>
                    <measurement group_id="O5" value="10.7"/>
                    <measurement group_id="O6" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 Visit 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="53.2"/>
                    <measurement group_id="O4" value="65.7"/>
                    <measurement group_id="O5" value="10.2"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="23.8"/>
                    <measurement group_id="O6" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="8.3"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="4.2"/>
                    <measurement group_id="O5" value="6.8"/>
                    <measurement group_id="O6" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="11.2"/>
                    <measurement group_id="O6" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="8.7"/>
                    <measurement group_id="O6" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="9.7"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="7.3"/>
                    <measurement group_id="O6" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="2.9"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="13.8"/>
                    <measurement group_id="O4" value="13.4"/>
                    <measurement group_id="O5" value="2.9"/>
                    <measurement group_id="O6" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 Visit 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="28.1"/>
                    <measurement group_id="O4" value="41.7"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="53.2"/>
                    <measurement group_id="O4" value="41.2"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="9.7"/>
                    <measurement group_id="O6" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="4.2"/>
                    <measurement group_id="O5" value="6.3"/>
                    <measurement group_id="O6" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="7.3"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="6.3"/>
                    <measurement group_id="O6" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5.6"/>
                    <measurement group_id="O5" value="2.9"/>
                    <measurement group_id="O6" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="5.6"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="7.9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 100 Visit 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="8.9"/>
                    <measurement group_id="O4" value="13.4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="19.2"/>
                    <measurement group_id="O4" value="11.6"/>
                    <measurement group_id="O5" value="20.4"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="10.2"/>
                    <measurement group_id="O6" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="9.7"/>
                    <measurement group_id="O6" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="9.2"/>
                    <measurement group_id="O6" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.9"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="8.3"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="10.2"/>
                    <measurement group_id="O6" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.4"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="9.2"/>
                    <measurement group_id="O6" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.4"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="7.8"/>
                    <measurement group_id="O6" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="5.8"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.4"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="3.9"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA mod 2011 0 or 1 response Visit 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="35.5"/>
                    <measurement group_id="O4" value="47.2"/>
                    <measurement group_id="O5" value="5.3"/>
                    <measurement group_id="O6" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12</title>
        <description>The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12</description>
        <time_frame>week 16, 20, 24,28,32,36,40,44,48,and Week 52</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12</title>
          <description>The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="176"/>
                <count group_id="O6" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 0 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.1"/>
                    <measurement group_id="O6" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 1 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="40.2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 2 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="27.8"/>
                    <measurement group_id="O6" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 3 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="11.3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 4 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="6.2"/>
                    <measurement group_id="O6" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 5 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 6 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.1"/>
                    <measurement group_id="O6" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 7 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 8 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 10 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: one, Regain PASI 75 Injection 12 (n=97,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 0 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 1 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="47.6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 2 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="42.9"/>
                    <measurement group_id="O6" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 3 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.8"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 4 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 6 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.8"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Two, Regain PASI 75 Injection 8 (n=21,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SoR: Three, Regain PASI 75 Injection 2 (n=0,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="NA">No evaluable participants</measurement>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
        <description>The development of anti-secunimubab anti-bodies will decrease a participant’s ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60</description>
        <time_frame>Baseline, weeks 12, 24, 52 and 60</time_frame>
        <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457150 mg- Induction Period Only(IPO)</title>
            <description>secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg - IPO</title>
            <description>secukinumab- 2 x 150mg injections per dose</description>
          </group>
          <group group_id="O3">
            <title>AIN457 150 mg - Fixed Interval (FI)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection</description>
          </group>
          <group group_id="O4">
            <title>AIN457 300 mg FI</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
          <group group_id="O5">
            <title>AIN457 150 mg- Start of Relapse (SoR)</title>
            <description>1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection</description>
          </group>
          <group group_id="O6">
            <title>AIN457 300 mg- SoR</title>
            <description>2 s.c. secukinumab 150 mg injections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
          <description>The development of anti-secunimubab anti-bodies will decrease a participant’s ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60</description>
          <population>Full analysis set (FAS) - All patients to whom study treatment was assigned</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="206"/>
                <count group_id="O6" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>INDUCTION-AIN457 150mg</title>
          <description>INDUCTION-AIN457 150mg</description>
        </group>
        <group group_id="E2">
          <title>INDUCTION-AIN457 300mg</title>
          <description>INDUCTION-AIN457 300mg</description>
        </group>
        <group group_id="E3">
          <title>ENTIRE-AIN457 150mg</title>
          <description>ENTIRE-AIN457 150mg</description>
        </group>
        <group group_id="E4">
          <title>ENTIRE-AIN457 300mg</title>
          <description>ENTIRE-AIN457 300mg</description>
        </group>
        <group group_id="E5">
          <title>ENTIRE-AIN457 150 mg SoR</title>
          <description>ENTIRE-AIN457 150 mg SoR</description>
        </group>
        <group group_id="E6">
          <title>ENTIRE-AIN457 300 mg SoR</title>
          <description>ENTIRE-AIN457 300 mg SoR</description>
        </group>
        <group group_id="E7">
          <title>FOLLOW UP-AIN457 150mg IPO</title>
          <description>FOLLOW UP-AIN457 150mg IPO</description>
        </group>
        <group group_id="E8">
          <title>FOLLOW UP-AIN457 300mg IPO</title>
          <description>FOLLOW UP-AIN457 300mg IPO</description>
        </group>
        <group group_id="E9">
          <title>FOLLOW UP-AIN457 150 mg</title>
          <description>FOLLOW UP-AIN457 150 mg</description>
        </group>
        <group group_id="E10">
          <title>FOLLOW UP-AIN457 300 mg</title>
          <description>FOLLOW UP-AIN457 300 mg</description>
        </group>
        <group group_id="E11">
          <title>FOLLOW UP-AIN457 150 mg SoR</title>
          <description>FOLLOW UP-AIN457 150 mg SoR</description>
        </group>
        <group group_id="E12">
          <title>FOLLOW UP-AIN457 300 mg SoR</title>
          <description>FOLLOW UP-AIN457 300 mg SoR</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>FIBROUS DYSPLASIA OF BONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PORTAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ABSCESS OF SALIVARY GLAND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CHRONIC TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>OOPHORITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>TONSILLITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PANCREATIC INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SPINAL CORD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>URINE ANALYSIS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CHONDROMALACIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>BENIGN BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CENTRAL NERVOUS SYSTEM INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VASCULAR HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>IGA NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VARICOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VULVA CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PEMPHIGUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PHOTOSENSITIVITY REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PUSTULAR PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GRANULOMATOSIS WITH POLYANGIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="137" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="120" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="126" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERCHLORHYDRIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GLYCOSURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>KETONURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ERYTHRODERMIC PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PAIN OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PUSTULAR PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="484"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this study is the lack of a placebo group; however, because the placebo response is very low in psoriasis, it is inappropriate to maintain patients on placebo for 52 weeks. .</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceutical</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

